AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AST-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AST-001 overview

AST-001 is under development for treatment of brain tumor, lung cancer with brain metastasis, acute lymphoblastic leukemia with brain metastasis, pancreatic cancer, hepatocellular carcinoma, gastric cancer, non-small cell lung cancer, breast cancer, esophageal cancer, colon cancer, rectal cancer, renal cell carcinoma, brain stromal tumor and prostate cancer. It is administered through intravenous route.

For a complete picture of AST-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.